Lates News

EachAI flash, China Post Securities released a research report on February 26, giving Aorete (605116.SH) a "buy" rating. The rating reasons mainly include: 1) Aoxintong smoothly entered the hospital, new products were approved to help improve the product structure; 2) Q3 profitability significantly improved, and both profit margin and quarter-on-quarter comparison improved significantly; 3) Emerging raw materials such as peptides and oligonucleotides are quickly increasing in volume. (Daily Economic News)